Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know

  • Sanofi SA SNY is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported.
  • Sanofi says that the market is well-served with the dominant role of BioNTech SE BNTXPfizer Inc PFE alliance and Moderna Inc MRNA.
  • Instead, the Company will focus on GlaxoSmithKline plc GSK-partnered protein-based COVID-19 vaccine candidate.
  • Related Content: Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine.
  • The decision to drop clinical development of the mRNA shot, acquired as part of its takeover of Translate Bio, came despite positive Phase 1/2 interim study results.
  • Related Link: Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights
  • The Company said it started testing an mRNA shot against seasonal influenza in humans in June and will launch follow-on clinical studies next year.
  • Interim results from the Phase 1/2 trial showed that neutralizing antibody levels increased four-fold two weeks after a second injection across all 3 dosages tested.
  • No safety concern has been observed, and the tolerability profile is comparable to that of other unmodified mRNA COVID-19 vaccines.
  • Also Read: Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism.
  • Price Action: SNY stock is up 0.17% at $48.20 during the premarket session on the last check Tuesday.
  • Photo by hakan german from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!